
    
      A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study
      of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small
      Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based,
      Concurrent Chemoradiation Therapy (PACIFIC)
    
  